Cefotiam
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Cefotiam.svg | |
| Cefotiam
| |
| Systematic (IUPAC) name | |
| (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)acetyl] amino}-3-{[1-(2-dimethylaminoethyl)tetrazol-5-yl] sulfanylmethyl}-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H23N9O4S3 |
| Mol. mass | 525.631 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 60% (intramuscular) |
| Protein binding | 40% |
| Metabolism | Nil |
| Half life | Approximately 1 hour |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous, intramuscular |
|
WikiDoc Resources for Cefotiam | |
|
Articles | |
|---|---|
|
Most recent articles on Cefotiam | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Cefotiam at Clinical Trials.gov Clinical Trials on Cefotiam at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Cefotiam
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating Cefotiam Risk calculators and risk factors for Cefotiam
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Cefotiam | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Cefotiam is a second-generation cephalosporin antibiotic.
External links
- Müller R, Böttger C, Wichmann G (2003). "Suitability of cefotiam and cefuroxime axetil for the perioperative short-term prophylaxis in tonsillectomy patients.". Arzneimittelforschung 53 (2): 126-32. PMID 12642969.
- Kolben M, Mandoki E, Ulm K, Freitag K (2001). "Randomized trial of cefotiam prophylaxis in the prevention of postoperative infectious morbidity after elective cesarean section.". Eur J Clin Microbiol Infect Dis 20 (1): 40-2. PMID 11245321.
- Shimizu S, Chen K, Miyakawa S (1996). "Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses.". Dermatology 192 (2): 174-6. PMID 8829507.
Antibacterials for systemic use: beta-lactam antibiotics - cephalosporins and related (J01D) | |
|---|---|
| First generation | Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazolin, Cefradine, Cefroxadine, Ceftezole |
| Second generation | Cefaclor, Cefamandole, Cefmetazole, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefuroxime |
| Third generation | Cefdinir, Cefditoren, Cefetamet, Cefixime, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpiramide, Cefpodoxime, Cefsulodin, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Latamoxef |
| Fourth generation | Cefepime, Cefpirome, Cefquinome |
| Fifth generation | Ceftobiprole |
| Other beta-lactam antibacterials | Monobactams (Aztreonam), Carbapenems (Parenteral - Meropenem, Ertapenem, Imipenem, Doripenem, Oral - Faropenem) |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
